sellWeak cluster of 510b5-1 plan
Mark W Hahn sold $811k of VRNA
Chief Financial Officer at Verona Pharma plc. 90,360 shares at an average of $8.98, traded Apr 29, 2025, filed May 1, 2025.
Warning score
24Value
$811k
90,360 shares
Holdings after
13,466,000
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +22Trade size$811k at market
- 0Share of holdings soldSold 0.7% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-25-043645, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 29, 2025 | MOption exercise Ordinary Shares10b5-1 | +229,512 | $0.00 | $0 | 13,556,360 | May 1, 2025 |
| Apr 29, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -90,360 | $8.98 | $811k | 13,466,000 | May 1, 2025 |
| Aug 7, 2024 | AGrant or award Restricted Share Unitsderivative10b5-1 | +1,200,000 | $0.00 | $0 | 1,200,000 | May 1, 2025 |
| Apr 29, 2025 | AGrant or award Restricted Share Unitsderivative10b5-1 | +675,000 | $0.00 | $0 | 675,000 | May 1, 2025 |
| Apr 29, 2025 | MOption exercise Restricted Share Unitsderivative10b5-1 | -229,512 | $0.00 | $0 | 445,488 | May 1, 2025 |
Related signals
Other insiders at Verona Pharma plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Verona Pharma plc | Christina Ackermann director | $24k 1,808 shares | -3% | |
| 36Weak | Verona Pharma plc | Michael Austwick director | $148k 11,288 shares | -47% | |
| 15Weak | Verona Pharma plc | James Aloysius Brady director | $11k 824 shares | -3% | |
| 31Weak | Verona Pharma plc | Kenneth Cunningham director | $142k 10,808 shares | -12% | |
| 30Weak | Verona Pharma plc | Lisa Deschamps director | $124k 9,464 shares | -10% | |
| 20Weak | Verona Pharma plc | David R Ebsworth director | $25k 1,904 shares | -0% | |
| 26Weak | Verona Pharma plc | Martin Edwards director | $142k 10,808 shares | -6% | |
| 26Weak | Verona Pharma plc | Andrew Fisher General Counsel | $126k 9,584 shares | -2% | |
| 27Weak | Verona Pharma plc | Mark W Hahn Chief Financial Officer | $2.7M 208,912 shares | -2% | |
| 17Weak | Verona Pharma plc | Kathleen A. Rickard Chief Medical Officer | $767k 58,336 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.